Protocol for Planning BA/BE Studies

Purpose

The purpose of this Standard Operating Procedure (SOP) is to outline the process for planning the design of Bioavailability (BA) and Bioequivalence (BE) studies in the pharmaceutical industry.

Scope

This SOP applies to all personnel involved in the planning, conduct, and oversight of BA and BE studies, including Principal Investigators, Study Directors, and Regulatory Affairs personnel.

Responsibilities

• The Principal Investigator (PI) or Study Director is responsible for overseeing the study design planning process.
• The Study Team, including statisticians, clinicians, pharmacologists, and regulatory experts, are responsible for providing input and expertise in study design.
• The Quality Assurance (QA) team is responsible for ensuring compliance with regulatory requirements and company SOPs.

Procedure

1. Define the objectives of the BA/BE study, including the specific drugs or formulations to be compared and the parameters to be measured.
2. Conduct a thorough review of relevant literature, regulatory guidelines, and previous studies to inform study design decisions.
3. Select an appropriate study design, considering factors such as study population, dosing regimen, sample size, and statistical methods.
4. Develop a detailed study protocol outlining all aspects of the study design, including inclusion and exclusion criteria, study endpoints, sample collection procedures, and data analysis plan.
5. Obtain necessary approvals from regulatory authorities and ethics committees before proceeding with the study.
6. Conduct a